Yubo International Biotech Limited
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.4K | $3.5K | $604.7K | $104.3K | $1.2M | $0 | $0 | $0 |
| Cost of Revenue | $4.2K | $822 | $185.5K | $51.6K | $423.7K | $114.3K | — | — |
| Gross Profit | $8.2K | $2.6K | $419.2K | $52.7K | $820.6K | $1.2M | — | — |
| Gross Margin | 66.1% | 76.3% | 69.3% | 50.5% | 65.9% | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | — | — | — | — | — | $57.7K | $48.0K | $58.0K |
| Operating Income | $-1.2M | $-1.8M | $-1.2M | $-1.2M | $-1.5M | $-711.8K | $-48.0K | $-58.0K |
| Operating Margin | -9,614.6% | -51,006.3% | -197.6% | -1,155.7% | -124.0% | — | — | — |
| Interest Expense | — | — | — | — | — | $53.0K | $100.0K | $86.0K |
| Pretax Income | $-1.2M | $-2.0M | $-1.2M | $-1.2M | $-1.5M | — | — | — |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $-1.1M | $-1.8M | $-1.2M | $-1.2M | $-1.5M | $-711.8K | $-148.0K | $-144.0K |
| Net Margin | -8,736.7% | -51,171.4% | -197.6% | -1,155.5% | -124.0% | — | — | — |
| EPS (Basic) | — | — | — | — | — | $0.00 | $-0.01 | $0.00 |
| EPS (Diluted) | $-0.01 | $-0.02 | $-0.01 | — | — | $0.00 | $-0.01 | $0.00 |
| Shares Outstanding (Basic) | — | — | — | 1.18B | 1.18B | — | — | 389.0M |
| Shares Outstanding (Diluted) | 139.6M | 119.8M | 119.8M | 1.18B | 1.18B | 389.3M | 11.8M | 389.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |